A population-based cohort study in Taiwan-use of insulin sensitizers can decrease cancer risk in diabetic patients?

Annals of Oncology

Volumn 24, Issue 2, 2013, Pages 523-530

  Kao, C H ^a   Sun, L M ^b   Chen, P C ^c   Lin, M C ^d   Liang, J A ^a,e   Muo, C H ^e   Chang, S N ^e,f   Sung, F C ^e  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b ZUOYING ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d E DA HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Cancer; Population based cohort study; Thiazolidinediones

Indexed keywords

ANTIDIABETIC AGENT; GLITAZONE DERIVATIVE; INSULIN SENSITIZING AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; ETHNIC GROUP; FEMALE; FOLLOW UP; HUMAN; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SEX DIFFERENCE; TAIWAN; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; COHORT STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTORS; TAIWAN; THIAZOLIDINEDIONES;

EID: 84873873495     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds472     Document Type: Article

References (34)

1. Fujiwara T, Horikoshi H. Troglitazone and related compounds: therapeutic potential beyond diabetes. Life Sci 2000; 67: 2405-2416.
2. Lehmann JM, Moore LB, Smith-Oliver TA et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-12956.
3. Feige JN, Gelman L, Michalik L et al. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 2006; 45: 120-159.
4. Bren-Mattison Y, Van Putten V, Chan D et al. Peroxisome proliferator-activated receptor-gamma (PPAR-(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene 2005; 24: 1412-1422.
5. Giannini S, Serio M, Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest 2004; 27: 982-991.
6. Ramos-Nino ME, MacLean CD, Littenberg B. Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC Med 2007; 5: 17.
7. Takeda Pharmaceutical Company Limited. Actos (pioglitazone hydrochloride) US package insert. Osaka: Takeda, August, 2004.
8. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR et al. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 2009; 32: 187-202.
9. Piccinni C, Motola D, Marchesini G et al. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011; 34: 1369-1371.
10. Lu JF, Hsiao WC. Does universal health insurance make health care unaffordable? Lessons from Taiwan. Health Aff (Millwood) 2003; 22: 77-88.
11. Cancer Statistics Annual Report: Taiwan Cancer Registry. http://tcr.cph.ntu.edu.tw/main.php?Page=N2 (15 August 2011, date last accessed).
12. Edwards BK, Ward E, Kohler BA et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010; 116: 544-573.
13. Liang JA, Sun LM, Yeh JJ et al. The association between malignancy and endstage renal disease in Taiwan. Jpn J Clin Oncol 2011; 41: 752-757.
14. Giovannucci E, Harlan DM, Archer MC et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010; 60: 207-221.
15. Vigneri P, Frasca F, Sciacca L et al. Diabetes and cancer. Endocr Relat Cancer. 2009; 16: 1103-1123.
16. Nemenoff RA. Peroxisome proliferator-activated receptor-gamma in lung cancer: defining specific versus "off-target" effectors. J Thorac Oncol 2007; 2: 989-992.
17. Han S, Inoue H, Flowers LC et al. Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells. Clin Cancer Res 2003; 9: 4627-4635.
18. Schiel R, Beltschikow W, Steiner T et al. Diabetes, insulin, and risk of cancer. Methods Find Exp Clin Pharmacol 2006; 28: 169-175.
19. Khan M, Mori M, Fujino Y et al. Site-specific cancer risk due to diabetes mellitus history: evidence from the Japan Collaborative Cohort (JACC) Study. Asian Pac J Cancer Prev 2006; 7: 253-259.
20. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005; 123: 993-999.
21. Ondrey F. Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res 2009; 15: 2-8.
22. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 2004; 5: 419-429.
23. Lefebvre AM, Chen I, Desreumaux P et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998; 4: 1053-1057.
24. Saez E, Tontonoz P, Nelson MC et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 1998; 4: 1058-1061.
25. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
26. Gerstein HC, Yusuf S, Bosch J et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006; 368: 1096-1105.
27. Lindberg M, Astrup A. The role of glitazones in management of type 2 diabetes. A dream or a nightmare? Obes Rev 2007; 8: 381-384.
28. Lewis JD, Ferrara A, Peng T et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916-922.
29. Ferrara A, Lewis JD, Quesenberry CP et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 2011; 34: 923-929.
30. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 2012; 35: 278-280.
31. Chang CH, Lin JW, Wu LC et al. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 2012; 55: 1462-1472.
32. Galli A, Ceni E, Mello T et al. Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin. Hepatology 2010; 52: 493-505.
33. Liao KF, Lai SW, Li CI et al. Diabetes mellitus correlates with increased risk of pancreatic cancer: A population-based cohort study in Taiwan. J Gastroenterol Hepatol 2012; 27: 709-713.
34. Chang C, Lu F, Yang YC et al. Epidemiologic study of type 2 diabetes in Taiwan. Diabetes Res Clin Pract 2000; 50 (Suppl 2): S49-S59.